Tag: Jeff Albers

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

pharmanewsdaily- July 15, 2020

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More